Study participants who reported tobacco use or had higher levels of biomarkers of tobacco exposure had a higher prevalence of the sexually transmitted infection, oral human papillomavirus type 16, according to a study in the Oct. 8 JAMA, a theme issue on infectious disease. HPV-16 is the most common cancer-causing variety of HPV.
08 October 2014 | Eurekalert
A recently published study claims to provide the first whole population analysis of the impact on genital warts of a national HPV vaccination programme – and this may be the best predictor of the longer-term, and more important, cancer prevention benefits to be seen in future years. The findings show a decline of 89.9% in admissions involving warts from 2006/7 to 2010/11 for girls aged 12-17 yrs, a decline of 72.7% for women aged 18-26, and a decline of 38% for men aged 18-14 (the indirect effect of female vaccination).
01 October 2014 | BMJ Group blogs
Six leading parliamentarians have today declared their support for vaccinating boys against HPV infection. Their joint statement said: "In our view, all adolescent boys should be offered the vaccine."
09 September 2014 | HPV Action
As effective treatments for HIV become more widely available in low-income and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV. An update on non-communicable diseases among HIV-positive populations in low-income and middle-income countries appears as a supplement to in JAIDS: Journal of Acquired Immune Deficiency Syndromes. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
14 August 2014 | Eurekalert Medicine & Health
Because no clinical trials address the question and published data are insufficient to support guidelines, the optimal antiretroviral therapy (ART) regimen for patients undergoing cancer chemotherapy remains unknown. But experts from Houston’s M.D. Anderson Cancer Center offer suggestions to help clinicians individualize therapy for each patient.
25 June 2014 | International AIDS Society
The European Commission has approved a new indication for Sanofi Pasteur MSD's human papillomavirus (HPV) vaccine Gardasil, giving the nod for it to be used in the prevention of anal cancer.
19 June 2014 | PMLive
Research by the University of California found a sex infection called trichomoniasis supported cancer growth when a team of scientists tested human prostate cells in a laboratory.
20 May 2014 | The Independent
Compassionate access schemes for these incredibly expensive drugs might facilitate access for selected patients but they are not truly compassionate in the way that the average person understands. If government subsidy looks unlikely, access schemes are retired, sometimes abruptly.
02 May 2014 | The Guardian
The efficacy of Gardasil® against anal disease - anal intraepithelial neoplasia (AIN) and anal cancer - was evaluated in a population of 598 men who have sex with men between 16 and 26 years of age naïve to HPV types 6, 11, 16 and 18. The efficacy of Gardasil® in reducing the incidence of anal precancerous lesions grades 2/3 (AIN 2/3) related to vaccine HPV types 6, 11, 16 & 18 was 74.9%. Median duration of follow-up was 2.15 years.
30 April 2014 | Sanofi Pasteur press release
Vaccines against cervical cancer work well even in sexually active women with H.I.V., a new study has found. It also found that women who already have one or two strains of the cancer-causing virus can be protected against others.
22 April 2014 | New York Times